University of Valencia

Sobi appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Retrieved on: 
Thursday, October 5, 2023
Senior, Knowledge, SEK, MBA, Physician, Nasdaq Stockholm, Research, Development, School, MD, Vanderbilt University School of Medicine, Medical Affairs Bureau, University, University Carlo Cattaneo, University of Valencia, Novo Nordisk, RDMA, Rare, Patient, Management, Pharmaceutical industry, Fine chemical, Swedish Orphan Biovitrum

STOCKHOLM, Oct. 5, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced the appointment of Lydia Abad-Franch, MD, MBA as Senior Vice President, Head of Research, Development and Medical Affairs (RDMA), and Chief Medical Officer.

Key Points: 
  • STOCKHOLM, Oct. 5, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced the appointment of Lydia Abad-Franch, MD, MBA as Senior Vice President, Head of Research, Development and Medical Affairs (RDMA), and Chief Medical Officer.
  • "Lydia is both an accomplished leader in rare diseases and an esteemed practicing medical doctor," said Guido Oelkers, CEO of Sobi.
  • "In addition, she has deep knowledge of the Sobi business as she has been with us for almost four years.
  • Lydia Abad-Franch said: "I am very excited to lead the research, development, and medical teams at Sobi, where we have a strong portfolio of transformative medicines for people with rare diseases.

Highlights - PEGA: Country hearing - Spain - Committee of Inquiry to investigate the use of Pegasus and equivalent surveillance spyware

Retrieved on: 
Thursday, December 1, 2022
University of Valencia, Computer science, Hearing, Committee, CNI, El secretario, University, Tutoring, Whaling

PEGA: Country hearing - Spain

Key Points: 
  • PEGA: Country hearing - Spain
    On 29 November PEGA Committee held a hearing on Spain, which was a part of several country-hearings organized by the Committee in line with the Plenary Decision establishing the PEGA Committee.
  • Programme of the hearings
    09.00 Opening remarks by the Chair of the Committee
    09.05 - 09.35 Panel 1: Experts
    Ignacio Cembrero, investigative journalist at El Confidential
    Andreu van den Eynde, Criminal lawyer, victim
    Gregorio Martin, Emeritus Professor of Computer Science, University of Valencia
    09.35 - 10.50 Discussion: Q&A session based on the principles of catch-the-eye and ping-pong
    10.50 - 11.10 Panel 2: Authorities
    Esperanza Casteleiro Llamazares, Director of the Spanish National Intelligence Agency (CNI)
    Juan Jess Torres Carbonell, Secretario General de Administracin Digital
    11.10 - 12.25 Discussion: Q&A session based on the principles of catch-the-eye and ping-pong
    12:25 Closing remarks by the Chair of the Committee

AnHeart Therapeutics Appoints Prof. Andrés Cervantes to Scientific Advisory Board

Retrieved on: 
Monday, January 24, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Coronavirus Scientific Advisory Board (Turkey), Tongji University, Research, Cholangiocarcinoma, Division, Journal of Thoracic Oncology, Hematology-Oncology and Stem Cell Transplantation Research Center, University of Colorado, University of Valencia, Breast, Oncology, AML, Department, University of California, Irvine School of Medicine, Gastrointestinal cancer, Lung cancer, Therapy, Ovarian cancer, ROS1, Company, Drug development, Doctor of Philosophy, University Hospital (Newark, New Jersey), SAB, Anschutz Medical Campus, Neoplasm, AXL, Department of Oncology, University of Cambridge, Teaching hospital, University, Large-cell lung carcinoma, Pharmaceutical industry, Hospital, NSCLC, Medicine

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical group company committed to developing novel precision oncology therapies, today announced the appointment of Prof. Andrs Cervantes to its Scientific Advisory Board.

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical group company committed to developing novel precision oncology therapies, today announced the appointment of Prof. Andrs Cervantes to its Scientific Advisory Board.
  • Andrs Cervantes is Professor of Medicine at the University of Valencia, Spain.
  • He completed his training in Medical Oncology at the University Hospital in Valencia, one of the leading centres in Spain in promoting and training in Medical Oncology since 1980.
  • He is currently an active investigator in the area of gastrointestinal cancer and new drug development.